The performance gap between clinical trials and patient treatment for dyslipidemia: A comprehensive review

Disease Management and Health Outcomes

Volumn 13, Issue 4, 2005, Pages 255-265

  Saseen, Joseph J ^a,c   Williams, Setareh A ^b   Valuck, Robert J ^a   O'Donnell, John C ^b   McDonough, Kenneth ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Department of Family Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DYSLIPIDEMIA; HUMAN; MONITORING; OUTCOMES RESEARCH; PATIENT COMPLIANCE; REVIEW;

EID: 23744439965     PISSN: 11738790     EISSN: 11738790     Source Type: Journal    
DOI: 10.2165/00115677-200513040-00004     Document Type: Review

References (79)

1. American Heart Association. Heart disease and stroke statistics: 2005 update. Dallas (TX): American Heart Association; 2004
2. Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large US employers in 1999. J Occup Environ Med 2003; 45 (1): 5-14
3. Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001; 141 (5): 727-34
4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486-97
5. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible popula-tion. Circulation 2002; 105 (2): 152-6
6. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110 (2): 227-39
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383-9
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 (20): 1301-7
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20): 1615-22
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335 (14): 1001-9
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339 (19): 1349-57
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
13. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360 (9346): 1623-30
14. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Out-comes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361 (9364): 1149-58
15. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-con-trolled trial. Lancet 2004; 364 (9435): 685-96
16. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350 (15): 1495-504
17. De Lemos JA, Blazing MA, Wiviott SD, et al. Early Intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16
18. Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003; 107 (17): 2185-9
19. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160 (4): 459-67
20. Rubins HB, Nelson DB, Noorbaloochi S, et al. Effectiveness of lipid-lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs System. Am J Cardiol 2003; 92 (10): 1177-82
21. Ayanian JZ, Landrum MB, McNeil BJ. Use of cholesterol-lowering therapy by elderly adults after myocardial infarction. Arch Intern Med 2002; 162 (9): 1013-9
22. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003; 348 (26): 2635-45
23. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvasta-tin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81 (5): 582-7
24. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92 (2): 152-60
25. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18 (4): 220-8
26. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lower-ing Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288 (23): 2998-3007
27. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336 (3): 153-62
28. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: atorvastatin versus revascularization treatment investigators. N Engl J Med 1999; 341 (2): 70-6
29. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285 (13): 1711-8
30. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a random-ized controlled trial. JAMA 2002; 287 (24): 3215-22
31. Straka RJ, Taheri R, Cooper SL, et al. Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy 2001; 21 (7): 818-27
32. Latts LM. Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans. Am J Med 2001; 110 Suppl. 6A: 17S-23S
33. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100 (6): 605-10
34. Harley CR, Williams SA, McDonough KL, et al. Cholesterol management in a population of managed care enrollees. J Clin Outcomes Manage 2003; 10 (3): 147-54
35. Meyer JW, O'Donnell JC, Patel PA, et al. Lipid lowering medications and achieving NCEP ATP III LDL-C goals in patients with dyslipidemia in a national managed care health plan: does efficacy translate into effectiveness? American Society Health System Pharmacists (ASHP) Summer meeting; 2003 May 31-Jun 4; San Diego (CA)
36. Valuck RJ, Williams SA, MacArthur M, et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 2003; 25 (11): 2936-57
37. Lewis BE, McDonough K. Dyslipidemia treatment among patients with coronary artery disease in a managed care organization. Am J Health Syst Pharm 2004; 61 (10): 1032-8
38. Watson-Heidari TL, Ershoff DH, Stacy J, et al. Treatment patterns among newly diagnosed coronary heart disease patients: correlates of lipid management. Value in Health 2003 May; 6 (3): 314 PCV21
39. Watson-Heidari TL, Ershoff DH, Sandman TB, et al. Patterns of pharmacological treatment among newly diagnosed coronary heart disease patients [abstract no. P49E]. American Society Health System Pharmacists (ASHP) Summer meeting; 2003 May 31- June 4; San Diego (CA)
40. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medica-tions: a cross-national study. JAMA 1998; 279 (18): 1458-62
41. White TJ, Chang E, Leslie S, et al. Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. J Manag Care Pharm 2002; 8 (3): 186-91
42. Fitterman LK, Williams SA. A descriptive review of statin utilization patterns. Paper (poster) presented at 2001 American Heart Association's 3rd Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; Washington, DC. Am Heart J 2002; 144 (5): 905-6
43. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000; 3: 417-26
44. Cozma LS, Ogunko A, Rees A. Secondary prevention of hypercholesterolaemia: results of an audit conducted in South Wales. Heart 2000; 84 (2): E3
45. Ayanian JZ, Landon BE, Landrum MB, et al. Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction. J Gen Intern Med 2002; 17 (2): 95-102
46. McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158 (11): 1238-44
47. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83 (9): 1303-7
48. Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111 (3): 185-91
49. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100 (2): 197-204
50. Hunninghake DB. Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guide-lines. Am J Cardiol 2001; 88 (8A): 37K-41K
51. Worz CR, Bottorff M. Treating dyslipidemic patients with lipid-modifying and combination therapies. Pharmacotherapy 2003; 23 (5): 625-37
52. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001; 24 (6): 467-74
53. Hunninghake D, Insull W, Toth P, et al. Coadministration of colesevelam hydro-chloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158 (2): 407-16
54. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110 (5): 352-60
55. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40 (3): 567-72
56. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25 (7): 1198-202
57. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89 (6): 672-8
58. Zetia [package insert]. North Wales (PA): Merck-Shering-Plough Pharmaceuticals, 2003 Mar
59. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospec-tive, randomized, double-blind trial. Circulation 2003; 107 (19): 2409-15
60. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91 (4): 418-24
61. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvas-tatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40 (12): 2125-34
62. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54 (3): 309-19
63. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholester-olemia. Am J Cardiol 2002; 90 (10): 1084-91
64. Fox J, Jones K. Lipid-lowering interventions in managed care settings. Am J Med 2001; 110 Suppl. 6A: 24S-30S
65. Yates S, Annis L, Pippins J, et al. Does a lipid clinic increase compliance with National Cholesterol Education Program Treatment Guidelines? Report of a case-matched controlled study. South Med J 2001; 94 (9): 907-9
66. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000; 20 (11): 1375-83
67. Hilleman DE, Monaghan MS, Ashby CL, et al. Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease. Pharmacotherapy 2001; 21 (11): 1415-21
68. Sullivan RA. Effects of provider feedback characteristics on patient adherence to NCEP LDL goal among coronary heart disease patients. Paper (poster) presented at 2001 American Heart Association's 3rd Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; Washington, DC
69. LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000; 9 (10): 1169-75
70. Murdoch M, Wilt TJ. Cholesterol awareness after case-finding: do patients really know their cholesterol numbers? Am J Prev Med 1997; 13 (4): 284-9
71. Cheng S, Lichtman JH, Amatruda J, et al. Knowledge of cholesterol targets and levels in patients with coronary heart disease. Paper (poster) presented at 2001 American Heart Association's 3rd Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; Washington, DC
72. Fugit RV, Resch ND. Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic. Am J Health Syst Pharm 2000; 57 (18): 1703-8
73. Grace KA, Swiecki J, Hyatt R, et al. Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors. Am J Health Syst Pharm 2002; 59 (11): 1077-82
74. Ito MK, Lin JC, Morreale AP, et al. Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol. Am J Health Syst Pharm 2001; 58 (18): 1734-9
75. Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm 2003; 9 (6): 544-51
76. Patel RJ, Gray DR, Pierce R, et al. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center. Am J Manag Care 1999; 5 (4): 465-74
77. Taylor AJ, Grace K, Swiecki J, et al. Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. Pharmacotherapy 2001; 21 (9): 1130-9
78. Jacobson TA, Griffiths GG, Varas C, et al. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examina-tion Survey. Arch Intern Med 2000; 160 (9): 1361-9
79. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998; 82 (1): 61-5